DE69836131T3 - Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen - Google Patents

Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen Download PDF

Info

Publication number
DE69836131T3
DE69836131T3 DE69836131.8T DE69836131T DE69836131T3 DE 69836131 T3 DE69836131 T3 DE 69836131T3 DE 69836131 T DE69836131 T DE 69836131T DE 69836131 T3 DE69836131 T3 DE 69836131T3
Authority
DE
Germany
Prior art keywords
delta3
polypeptide
amino acid
protein
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69836131.8T
Other languages
German (de)
English (en)
Other versions
DE69836131T2 (de
DE69836131D1 (de
Inventor
Sean McCarthy
David Gearing
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
Millennium Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27125549&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DE69836131(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/872,855 external-priority patent/US6121045A/en
Application filed by Millennium Pharmaceuticals Inc filed Critical Millennium Pharmaceuticals Inc
Publication of DE69836131D1 publication Critical patent/DE69836131D1/de
Publication of DE69836131T2 publication Critical patent/DE69836131T2/de
Application granted granted Critical
Publication of DE69836131T3 publication Critical patent/DE69836131T3/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Cardiology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DE69836131.8T 1997-04-04 1998-04-06 Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen Expired - Lifetime DE69836131T3 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US83263397A 1997-04-04 1997-04-04
US832633 1997-04-04
US08/872,855 US6121045A (en) 1997-04-04 1997-06-11 Human Delta3 nucleic acid molecules
US872855 1997-06-11
PCT/US1998/006775 WO1998045434A1 (en) 1997-04-04 1998-04-06 Novel human delta3 compositions and therapeutic and diagnostic uses therefor
EP98915305.1A EP0972041B2 (en) 1997-04-04 1998-04-06 Novel human delta3 compositions and therapeutic and diagnostic uses therefor

Publications (3)

Publication Number Publication Date
DE69836131D1 DE69836131D1 (de) 2006-11-23
DE69836131T2 DE69836131T2 (de) 2007-08-30
DE69836131T3 true DE69836131T3 (de) 2017-06-14

Family

ID=27125549

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69836131.8T Expired - Lifetime DE69836131T3 (de) 1997-04-04 1998-04-06 Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen

Country Status (8)

Country Link
EP (1) EP0972041B2 (enExample)
JP (1) JP2001521382A (enExample)
AT (1) ATE342358T1 (enExample)
AU (1) AU6952498A (enExample)
CA (1) CA2285020A1 (enExample)
DE (1) DE69836131T3 (enExample)
ES (1) ES2275304T3 (enExample)
WO (1) WO1998045434A1 (enExample)

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0861261B9 (en) 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
US5780300A (en) * 1995-09-29 1998-07-14 Yale University Manipulation of non-terminally differentiated cells using the notch pathway
US20060122373A1 (en) 1997-04-04 2006-06-08 Millennium Pharmaceuticals, Inc. Delta3, FTHMA-070, Tango85, Tango77, SPOIL,NEOKINE, Tango129 and integrin alpha subunit protein and nucleic acid molecules and uses thereof
WO1998051799A1 (en) * 1997-05-14 1998-11-19 Asahi Kasei Kogyo Kabushiki Kaisha Novel differentiation inhibitor
EP1100899A2 (en) * 1998-07-27 2001-05-23 Amgen Inc. Delta-related polypeptides
US6703221B1 (en) 1999-08-19 2004-03-09 Chiron Corporation Notch receptor ligands and uses thereof
JP2003507029A (ja) * 1999-08-19 2003-02-25 カイロン コーポレイション Ｎｏｔｃｈレセプターリガンドおよびその使用
GB9927331D0 (en) 1999-11-18 2000-01-12 Fluorescience Ltd Assay for measuring enzyme activity in vivo
GB9927328D0 (en) 1999-11-18 2000-01-12 Lorantis Ltd Immunotherapy
US6984522B2 (en) 2000-08-03 2006-01-10 Regents Of The University Of Michigan Isolation and use of solid tumor stem cells
US8044259B2 (en) 2000-08-03 2011-10-25 The Regents Of The University Of Michigan Determining the capability of a test compound to affect solid tumor stem cells
EP1438402A2 (en) * 2001-08-22 2004-07-21 Galapagos Genomics N.V. Modulators of bone homeostasis identified in a high-throughput screen
JP2003245084A (ja) 2001-12-20 2003-09-02 Morinaga Milk Ind Co Ltd 脳梁又は精子の形成不全の診断及び治療に有用な新規遺伝子、並びにその用途
US8048418B2 (en) 2004-10-29 2011-11-01 Regeneron Pharmaceuticals, Inc. Therapeutic methods for inhibiting tumor growth with combination of Dll4 antagonists and VEGF antagonists
US7906116B2 (en) 2005-09-01 2011-03-15 Parkash Gill Methods for using and identifying modulators of Delta-like 4
US7723477B2 (en) 2005-10-31 2010-05-25 Oncomed Pharmaceuticals, Inc. Compositions and methods for inhibiting Wnt-dependent solid tumor cell growth
PT2500360E (pt) 2005-10-31 2015-10-15 Oncomed Pharm Inc Composições e métodos para diagnóstico e tratamento do cancro
CA2654000A1 (en) 2006-06-06 2008-05-22 Genentech, Inc. Anti-dll4 antibodies and methods using same
US7750124B2 (en) 2006-09-29 2010-07-06 Oncomed Pharmaceuticals, Inc. Anti-human DLL4 antibodies and compositions
NO347649B1 (no) 2006-12-14 2024-02-12 Regeneron Pharma Humant antistoff eller antistoff fragment som spesifikt binder human deltaliknende ligand 4 (hDII4), nukleinsyremolekyl som koder for slike og vektor og vert-vektorsystemer, samt fremgangsmåte for fremstilling, sammensetning og anvendelse.
EP2106439B1 (en) 2007-01-24 2014-11-12 The Regents of the University of Michigan Compositions and methods for treating and diagnosing pancreatic cancer
MX2011003183A (es) 2008-09-26 2011-04-21 Oncomed Pharm Inc Agentes que se unen a receptor encrespado y usos de los mismos.
EP2356270B1 (en) 2008-11-07 2016-08-24 Fabrus Llc Combinatorial antibody libraries and uses thereof
EP3485908B1 (en) 2009-10-16 2021-08-18 Mereo BioPharma 5, Inc. Therapeutic combination and use of dll4 antagonist antibodies and anti-hypertensive agents
TWI535445B (zh) 2010-01-12 2016-06-01 安可美德藥物股份有限公司 Ｗｎｔ拮抗劑及治療和篩選方法
DK3342786T3 (en) 2010-01-29 2021-09-27 Chugai Pharmaceutical Co Ltd Anti-dll3-antistof
KR20130043102A (ko) 2010-04-01 2013-04-29 온코메드 파마슈티칼스, 인크. 프리즐드-결합 작용제 및 그의 용도
US8551479B2 (en) 2010-09-10 2013-10-08 Oncomed Pharmaceuticals, Inc. Methods for treating melanoma
HRP20190044T1 (hr) 2011-09-23 2019-02-22 Oncomed Pharmaceuticals, Inc. Agensi koji vežu vegf/dll4 i njihove uporabe
HK1212216A1 (en) 2012-10-23 2016-06-10 Oncomed Pharmaceuticals, Inc. Methods of treating neuroendocrine tumors using wnt pathway-binding agents
AU2013337811A1 (en) 2012-10-31 2015-05-14 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a DLL4 antagonist
HK1211887A1 (en) 2013-02-04 2016-06-03 Oncomed Pharmaceuticals, Inc. Methods and monitoring of treatment with a wnt pathway inhibitor
US9168300B2 (en) 2013-03-14 2015-10-27 Oncomed Pharmaceuticals, Inc. MET-binding agents and uses thereof
MX382902B (es) 2014-10-31 2025-03-13 Oncomed Pharm Inc Inhibidor de la vía noth en combinación con un agente inmunoterapéutico para usarse en el tratamiento de cáncer.
WO2017053705A1 (en) 2015-09-23 2017-03-30 Oncomed Pharmaceuticals, Inc. Methods and compositions for treatment of cancer
WO2019131988A1 (en) 2017-12-28 2019-07-04 Chugai Seiyaku Kabushiki Kaisha Cytotoxicity-inducing therapeutic agent

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL101728A (en) 1991-05-03 2007-08-19 Univ Yale Human Abandonment and Delta, Restrictive Areas of Effect in Tophoric Proteins, and Methods Based on Them
US5786158A (en) 1992-04-30 1998-07-28 Yale University Therapeutic and diagnostic methods and compositions based on notch proteins and nucleic acids
EP0861261B9 (en) * 1995-06-28 2010-02-24 Imperial Cancer Research Technology Limited Nucleotide and protein sequences of vertebrate delta genes and methods based thereon
DE69635899T2 (de) * 1995-11-17 2006-11-23 Asahi Kasei Kabushiki Kaisha Polypeptid, das die differenzierung unterdrueckt

Also Published As

Publication number Publication date
DE69836131T2 (de) 2007-08-30
ATE342358T1 (de) 2006-11-15
DE69836131D1 (de) 2006-11-23
CA2285020A1 (en) 1998-10-15
EP0972041B2 (en) 2017-01-18
AU6952498A (en) 1998-10-30
WO1998045434A1 (en) 1998-10-15
JP2001521382A (ja) 2001-11-06
EP0972041A1 (en) 2000-01-19
ES2275304T3 (es) 2007-06-01
EP0972041B1 (en) 2006-10-11

Similar Documents

Publication Publication Date Title
DE69836131T3 (de) Neue menschliche delta3-zusammensetzung und deren therapeutische und diagnostische verwendungen
DE69735939T2 (de) Fhit proteine und nukleinsäuren sowie darauf basierende verfahren
DE69926764T2 (de) Methoden zur bestimmung von komponenten zur modulation des körpergewichts
DE69534402T2 (de) Apoptose-proteasen 3 und 4, ähnlich dem umwandlungsenzym für interleukin-1beta
DE60034450T2 (de) 22025, eine neue menschliche zyklische nukleotiden phosphodiesterase
DE69838905T2 (de) Transkriptionsfaktor islet-brain 1 (ib1)
US20110230392A1 (en) Novel narc sc1, narc 10a, narc 1, narc 12, narc 13, narc17, narc 25, narc 3, narc 4, narc 7, narc 8, narc 11, narc 14a, narc 15, narc 16, narc 19, narc 20, narc 26, narc 27, narc 28, narc 30, narc 5, narc 6, narc 9, narc 10c, narc 8b, narc 9, narc2a, narc 16b, narc 1c, narc 1a, and narc 25 molecules and uses therefor
DE69837085T2 (de) Crsp-proteine (cystein-reiche, sekretierte proteine), die dafür kodierenden nukleinsäuren und ihre verwendungen
JP2010004892A (ja) 新規なヒトデルタ３組成物ならびにそれらの治療および診断への使用方法
US20030180784A1 (en) Novel human Delta3 compositions and therapeutic and diagnostic uses therefor
US5885776A (en) Glaucoma compositions and therapeutic and diagnositic uses therefor
WO1998004590A1 (en) Conservin compositions and therapeutic and diagnostic uses therefor
DE60214867T2 (de) Histonedeacetylase 9
DE60125148T2 (de) Fctrx genannte proteine und dafür kodierende nuklein säure
DE69931345T2 (de) Gen, welches für neues transmembranprotein kodiert
US6146827A (en) Rath genes and polypeptides and methods for the treatment and diagnosis of immune disorders
RU2273645C2 (ru) Полипептид ожирения (ов)(варианты), его аналог (варианты) и слитый белок (варианты), изолированная молекула нуклеиновой кислоты, молекула днк, рекомбинантный вектор клонирования, рекомбинантный вектор экспрессии, фармацевтическая композиция, моноклональное и поликлональное антитело
CA2271235A1 (en) Glaucoma-associated protein and corresponding nucleic acid and their therapeutic and diagnostic uses
WO1998046748A1 (en) Therapeutic compositions and diagnostic assays for diseases involving trbp
DE60124380T2 (de) Angiogenese-assoziierte proteine und dafür kodierende nukleinsäure
MXPA01004903A (es) Agentes que interactuan con canales del potasio y usos de los mismos.
DE60125569T2 (de) 13245, eine neue, humane protein kinase vom typ myotonische dystrophie protein kinase und anwendungen davon
US5846780A (en) Murine RATH gene
DE60024862T2 (de) "insulinabhängiges sequenz dna bindendes protein-1" (irsdbp-1), dafür kodierendes gen und ihre verwendungen
DE60319693T2 (de) Marker fur lungentumoren

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: MILLENNIUM PHARMACEUTICALS,INC., CAMBRIDGE, MA, US

8363 Opposition against the patent
8328 Change in the person/name/address of the agent

Representative=s name: MOSELPATENT TRIERPATENT, 54290 TRIER

8328 Change in the person/name/address of the agent

Representative=s name: PATENTANWAELTE SERWE & DR. WAGNER, 54290 TRIER